Adolescent ; Biopsy, Fine-Needle ; Chromosomes, Human, Pair 18 ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Oncogene Proteins, Fusion ; genetics ; Proto-Oncogene Proteins c-bcl-2 ; metabolism ; Sarcoma, Synovial ; genetics ; metabolism ; pathology ; Soft Tissue Neoplasms ; genetics ; metabolism ; pathology ; Translocation, Genetic ; Vimentin ; metabolism

OBJECTIVETo investigate the expression and the subcellular localization of HDAC9 in different brain regions of mice after cerebral ischemic injury and explore the association between HDAC9 and ischemic stroke.

METHODSTwenty-one male C57BL/6 mice were randomly divided into sham-operated group (n=9) and operated group (n=12). In the latter group, the mice with Zea-Longa neurological deficit scores of 2 or 3 following middle cerebral artery occlusion (MCAO) were assigned into MCAO group (n=9). Immunofluorescence was performed to investigate the subcellular localization of HDAC9 in the brain tissues on day 3 after MCAO. Western blotting and qRT-PCR were used to analyze the expression of HDAC9 in different regions of the brain. Results Immunofluorescence showed more intense HDAC9 expressions in the brain tissues around the infarct focus, and in the cells surrounding the infarct, HDAC9 expression was obviously increased in the cytoplasm and reduced in the cell nuclei. Compared with the other brain regions, the ipsilesional cortex with MCAO showed more abundant HDAC9 expressions at both the mRNA and protein levels (P<0.05).

CONCLUSIONHDAC9 may be closely related to cerebral ischemic injury and participate in the pathophysiological process of ischemic stroke.

OBJECTIVETo assess the antihypertensive effect and safety on medicine named 'Beijing Hypertensive No. 0' in a three-year treatment of primary hypertension.

METHODSA community-based intervention study was conducted. The antihypertensive effects and adverse events were observed.

RESULTS4000 patients with primary hypertension were randomly divided into two groups with 1529 patients treated with 'Beijing Hypertensive No. 0' and 976 patients treated with other antihypertensive drugs, among which 946 and 853 patients in the two groups completed the three-year study. After treatment, the systolic blood pressure decreased 13 mm Hg and 7 mm Hg while diastolic blood pressure decreased 8 mm Hg and 4 mm Hg in the 'No. 0' group and controlled group respectively. After three years of treatment, 90.0% and 79.5% in the 'No.0' group and in the control group had reached the BP 'fulfillment criteria', which were much higher than the baseline data. Side effects occurred in 33/1274 (2.6%) cases during three years' treatment with most commonly seen as dizziness, headache, palpitation and weakness. No serious adverse reactions occurred. There were some positive effects after treated by 'No. 0', including 0.13 mmol/L decrease of TC, 0.70 mmol/L decrease of LDL-C and an average 0.12 mmol/L increase of HDL-C. All of these changes were statistically significant. There were also opposite effects as 0.13 mmol/L increase of TG, 0.24 mmol/L increase of K+, and 0.88 mmol/L increase of Na+ on average, which were also statistically significant.

CONCLUSIONCompared with the conventional treatment, this treatment of 'Beijing Hypertensive No.0' was more convenient, safe and effective in treating mild to moderate primary hypertension in the community.

Aged ; Antihypertensive Agents ; adverse effects ; therapeutic use ; Female ; Follow-Up Studies ; Humans ; Hypertension ; drug therapy ; Male ; Safety

Objective To compare the cost-effectiveness of two anti-hypertensive therapy regimens,Compound anti-hypertensive tablets and other common anti-hypertensive agents,in the treatment program of Primary Hypertension.Methods We conducted a cost-effectiveness analysis based on a community trial.Two communities'primary hypertensive patients were enrolled to receive different therapy drugs:Compound anti-hypertensive tablets(Group A)or other common anti-hypertensive agents(Group B).Blood pressure,medicine used,and adverse drug reactions were observed and recorded for one year,and then costeffectiveness ratio of the two groups and incremental ratio were calculated.We considered a 30%drug price fluctuating load to make the sensitivity analysis.Results 2505 cases were enrolled with 1529 cases in group A and 976 cases in group B.The cost-effectiveness ratios were 418.1 and 1057.7 for Group A and B respectively while the incremental cost-effectiveness of Group B vs.Group A was 19 202.2.The results were insensitive to variation in the costs of drugs over clinically reasonable ranges.Conclusion Compound anti-hypertensive tablets appeared to be relatively cost-effective when compared to common drugs for the treatment of primary hypertension.

The present study aimed to investigate the difference in the voltage dependent potassium channel (Kv) expression in lymphocytes between the spontaneously hypertensive rats (SHRs) and Wistar rats. Peripheral blood lymphocytes were collected from 10 male SHRs and 10 normotensive Wistar rats aged 16 weeks. First, by using the patch-clamp technique, Kv channel current was recorded in freshly isolated lymphocytes from SHRs and normotensive Wistar rats. Total RNAs were extracted from lymphocytes by using TRIzol reagent. Real-time PCR was used to determine the expression of Kv1.3 mRNA and Western blot technique was used to measure the expression of Kv1.3 protein in lymphocytes from SHRs and normotensive Wistar rats. The results showed that: (1) The current density of Kv channel in the step voltage of +60 mV was higher in lymphocytes from SHRs than that from the normotensive Wistar rats [(119+/-10) pA/pF vs (56+/-9) pA/pF, P<0.05]; (2) The level of Kv1.3 mRNA expression in lymphocytes from SHRs was significantly increased compared with that of the normotensive Wistar rats (0.0313+/-0.017 vs 0.0023+/-0.005, P<0.05); (3) The expression of Kv1.3 protein was significantly elevated in lymphocytes (1.02+/-0.04 vs 0.41+/-0.03, P<0.05) from SHRs compared with that of the normotensive Wistar rats. The results obtained demonstrate that the lymphocytes Kv channels are increased in SHR, and the Kv channel may be involved in activation of lymphocytes from SHR.
Animals ; Hypertension ; metabolism ; Kv1.3 Potassium Channel ; genetics ; metabolism ; Lymphocytes ; metabolism ; Male ; Patch-Clamp Techniques ; RNA, Messenger ; genetics ; metabolism ; Rats ; Rats, Inbred SHR ; Rats, Wistar

Bias ; Confounding Factors (Epidemiology) ; Epidemiologic Methods ; Humans

Case-Control Studies ; China ; Cohort Studies ; Epidemiologic Methods ; Epidemiology ; history ; History, 19th Century ; History, 20th Century ; Humans ; Randomized Controlled Trials as Topic

OBJECTIVETo study the effects of telmisartan on voltage dependant potassium channel (Kv) expression in lymphocytes from spontaneously hypertensive rat (SHR).

METHODSPeripheral blood was collected from male SHR aged 16 and 4 weeks. Peripheral lymphocytes were separated from heparinized whole blood by standard Ficoll-Hypaque density gradient centrifugation. The whole-cell Kv currents were recorded with patch-clamp technique in the absence and presence of telmisartan(10, 30, 100 µmol/L). Real-time PCR was used to determine Kv1.3 mRNA expression in lymphocytes.

RESULTS(1) The currents density of Kv was higher in lymphocytes from 16 weeks-old SHR [ (119.0 ± 9.6) pA/pF] than from 4 weeks-old SHR [(59.0 ± 7.2) pA/pF, P < 0.05]. (2) Currents density was positively correlated with systolic blood pressure in 16 weeks-old SHR (r = 0.837, P < 0.05). (3) The lymphocytes Kv 1.3 mRNA expression was significantly higher in 16-weeks-old SHR than in 4-weeks-old SHR (P < 0.05). (4) Telmisartan reduced the whole-cell Kv currents in a concentration-dependent manner (10.5 ± 3.4)% at 10 µmol/L, (45.8 ± 3.7)% at 30 µmol/L and (81.6 ± 4.2)% at 100 µmol/L, P < 0.01.

CONCLUSIONSThe lymphocyte Kv channel is upregulated in 16 weeks-old SHR suggesting a role of Kv in the pathophysiology of hypertension. Kv current in lymphocyte could be significantly blocked by telmisartan in a concentration dependent manner.

4-Aminopyridine ; pharmacology ; Animals ; Benzimidazoles ; pharmacology ; Benzoates ; pharmacology ; Lymphocytes ; drug effects ; metabolism ; Male ; Patch-Clamp Techniques ; Potassium Channels, Voltage-Gated ; drug effects ; Rats ; Rats, Inbred SHR ; metabolism

Disease ; etiology ; Epidemiology ; Humans

OBJECTIVETo investigate the expression of Abi1 in hepatocellular carcinoma (HCC) and the correlation between its expression level and clinical pathological characteristics as well as prognosis of HCC.

METHODSAbi1 expression was determined at both mRNA and protein levels in 40 HCC tissues and their corresponding para carcinomatous liver tissues by RT-PCR and immunohistochemistry. The correlations between Abi1 expression levels and pathological characteristics as well as prognosis were also analyzed.

RESULTSThe expression level of Abi1 mRNA in HCC tissues were significantly higher than those in corresponding para carcinomatous liver tissue (P < 0.05), and the expression level of Abi1 mRNA in nodular HCC tissues were also significantly higher than those in solitary large HCC tissues. Immunohistochemistry results showed that Abi1 protein located in cytoplasm of HCC cells and the expression level of Abi1 protein were significant positive correlated with the number of HCC, capsular formation, venous invasion and Edmondson-Steiner grade (P < 0.05). Combined with follow-up data, the results also showed that HCC patients with high Abi1 protein expression had a higher risk of invasion/metastasis and a shorter survival than those with low Abi1 protein expression (P < 0.05).

CONCLUSIONSExpression level of Abi1 is up-regulated in HCC tissues compared with corresponding para carcinomatous liver tissue and the expression level of Abi1 is significantly correlated with the number of tumor, capsular formation, venous invasion, Edmondson-Steiner grade and prognosis of HCC.

Adaptor Proteins, Signal Transducing ; genetics ; metabolism ; Adult ; Aged ; Carcinoma, Hepatocellular ; metabolism ; pathology ; Cytoskeletal Proteins ; genetics ; metabolism ; Female ; Follow-Up Studies ; Humans ; Liver Neoplasms ; metabolism ; pathology ; Male ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Prognosis ; RNA, Messenger ; genetics